Tumor cell contamination of stem cell products can contribute to tumor relapse following high-dose chemotherapy and stem cell rescue. Numerous techniques have been used to remove the tumor cells from stem cell products with the objective of prolonging relapse-free survival. However, to date these techniques have been relatively ineffectual and/or toxic to hematopoietic stem and progenitor cells. The differential infectivity of adenovirus (Adv) vectors for breast cancer cells, compared with hematopoietic cells, has suggested that Adv-p53 might provide an effective purging strategy. To facilitate the use of Adv-p53 as a clinical strategy, we undertook studies to determine the parameters necessary for optimal stem cell product purging. The parameters studied were the particle number to nucleated cell ratio, the duration of coincubation, the incubation volume, and the presence or absence of hematopoietic progenitor cells. We have found that these parameters are interdependent and conclude that a 4-hour coincubation with an Adv-p53 particle to nucleated cell ratio of 2000:1 with 2 ϫ 10 8 nucleated cells/mL is optimal for tumor cell purging. Furthermore, this appeared to be a safe procedure, with total loss of clonogenic growth of breast cancer cells as well as no significant effect on progenitor cell function as determined by granulocyte-macrophage colony-forming unit assays. Cancer Gene Therapy (2000) 7, 197-206
T reatment with high-dose chemotherapy (HDT) followed by stem cell rescue is used increasingly in patients with breast cancer. [1] [2] [3] [4] [5] However, a high relapse rate after HDT is still observed, especially in women with high risk and metastatic breast cancer. 6 In most cases, failure of the conditioning regimen to eradicate disease remains the primary cause of disease recurrence. There is strong evidence from gene-marking studies that tumor cell (TC) contamination of the graft can also contribute to cancer recurrence, 7 although such studies have not been undertaken with breast cancer transplant patients. 8, 9 TC can be detected not only in the bone marrow (BM) of advanced breast cancer patients (20 -70%) but also in the BM of patients with localized breast cancer (20 -45%) using sensitive immunocytochemical analyses 9 or reverse transcriptase-polymerase chain reaction assays. 10 -14 Mobilized peripheral blood stem cell (PSC) products are used as an alternative to BM stem cells and result in a more rapid neutrophil recovery 3, 5 following HDT. Initially, it appeared that PSC products were free of TC; however, recent studies have demonstrated that cancer cells can also be detected in mobilized PSC products. 15, 16 Although PSC products have a reduced level of TC contamination compared with BM cells, 5, 15, 17, 18 they are frequently contaminated with TC, and novel strategies for PSC purging are needed.
Clinically, mutations of wild-type (wt) p53 are observed in 30 -50% of breast cancer patients and functional inactivation of p53 may occur in 30% of these individuals. 19 Transduction of wt p53 into TC with mutated p53 can suppress the malignant phenotype and induce cell death via apoptosis. 20 -22 Replication-deficient recombinant human adenoviruses (Adv) have recently been used as vectors for wt human p53 gene therapy. 23, 24 Studies evaluating Adv-p53 in clinical trials are underway. 25 Because of the potential for contaminating TC to contribute to disease relapse and the minimal effect of Adv on hematopoietic stem cell function, 26, 27 we investigated the parameters required for optimal Adv-p53 purging of stem cell products. We demonstrate that the Adv-p53 to cell ratio, the incubation volume, the duration of virus-cell incubation, and the presence of cells from PSC products are all critical parameters for a successful purging protocol.
MATERIALS AND METHODS

Recombinant Adv
Replication-deficient Adv vectors encoding Escherichia coli ␤-galactosidase (␤-gal) or wt human p53 were provided by Canji, Inc. (San Diego, Calif). Adv-␤-gal and Adv-p53 were prepared, purified, and titrated as reported previously. 28, 29 Briefly, in the Adv vectors, a portion of the E1a and E1b region of human Adv type 5 was replaced with the ␤-gal or p53 gene under the transcriptional control of the cytomegalovirus promoter. Adv-␤-gal and Adv-p53 were produced in the 293 human embryonic kidney cell line and purified by ultracentrifugation or column chromatography. The titers of the viral stocks used were 1.1-5.8 ϫ 10 10 infectious units/mL by dilution assay on 293 cells and 4.6 -10 ϫ 10 11 particle numbers (PN)/ mL. These studies quantitated Adv numbers using analytical anion-exchange high pressure liquid chromatography. 30 This technique assesses the PN in both diluted and concentrated samples over a wide dynamic range. 31 The viral particles are eluted in a single peak that contains most of the infectious virions, providing a sensitive technique that overcomes the limitations of previous methods and has become the quantitation of choice by the Food and Drug Administration. 32 Adv-␤-gal and Adv-p53 were stored in a buffer solution containing 2% sucrose and 2 mM MgCl 2 at Ϫ70°C.
Human breast cancer cell lines
The MDA-MB-231, -435, and -468 human breast cancer cell lines as well as the SKBR-3 and MCF-7 human breast cancer cell lines were obtained from the American Type Culture Collection (Manassas, Va). MDA-MB-231, MDA-MB-435, and SKBR-3 cells were maintained in Dulbecco's minimal essential media (DMEM) containing 50% Ham's F-12, 10% fetal bovine sera (FBS), 1% L-glutamine, and 40 g/mL gentamicin at 37°C, 5% CO 2. The MDA-MB-468 cells were maintained in Kaighn's DMEM containing 50% Ham's F-12, 10% FBS, 1% L-glutamine, 40 g/mL gentamicin, and 0.2 infectious units/mL insulin at 37°C, 5% CO 2 . The MCF-7 cells were maintained in DMEM containing 10% FBS, 1% Lglutamine, and 40 g/mL gentamicin at 37°C, 5% CO 2 .
Adv infection of breast cancer cell lines
Cells were harvested from 30% to 50% confluent tissue culture flasks and adjusted to 5 ϫ 10 4 cells/mL. Adv-p53 or Adv-␤-gal was added at the identified virus to TC ratio (PN to TC) in a measured volume of complete media in round-bottom polypropylene tubes (Becton Dickinson, Lincoln Park, NJ) and compared with control mock-infected cultures. After incubation at 37°C, 5% CO 2 , the number of cells sufficient to result in 50 -100 colonies (dependent upon the cell line) was cultured in 60-mm round tissue culture plates (n ϭ 3) in a 5-mL volume of complete media at 37°C, 5% CO 2 for a sufficient time to allow for colony formation (10 -18 days depending upon the cell line). Colonies were fixed and stained for 2 hours with a 70% ethanol solution containing 0.5% methylene blue, and the colony number was counted using a Biotran automatic count totalizer (New Brunswick Scientific, Edison, NJ). The percentage of inhibition was defined as follows: (number colonies in treated cultures/number colonies in untreated control cultures) ϫ 100.
Effect of PSC on Adv-p53 induced TC clonogenicity
Human PSC without histological evidence of TC infiltration were obtained from non-Hodgkin's lymphoma patients who were undergoing autologous PSC harvesting and mobilized with granulocyte colony-stimulating factor (G-CSF) after receiving signed informed consent. PSC 42 .5:1) in 1 mL of complete medium for 4 hours in round-bottom polypropylene tubes at 37°C, 5% CO 2 . After incubation, the cells were washed three times with complete media and aliquoted equally into three 60-mm round tissue culture dishes. The cells were cultured in a 5-mL volume of complete media at 37°C, 5% CO 2 . After 11 days of incubation (a sufficient time to allow for colony formation), the plates were fixed and stained as described above.
Hematopoietic colony-forming assays
After incubation with TC and Adv-p53, the PMNC were harvested and the numbers of cells were determined using a System 9000 Hematology Series cell counter (Serono-Baker Diagnostic, Allentown, Penn). Granulocyte-macrophage colony-forming units (GM-CFU) were quantitated in a soft agar culture system. 26, 27 A total of 100,000 PMNC were cultured in 1 mL of 0.3% agar-Iscove's modified Dulbecco's medium containing 25% FBS, 100 U/mL penicillin, 100 g/mL streptomycin, and 5 ϫ 10 Ϫ5 M 2-mercaptoethanol. A total of 200 U/mL recombinant human interleukin, 3200 U/mL recombinant human GM-CSF, and 200 U/mL recombinant human G-CSF were added as sources of colony-stimulating activity. The cells were plated in 35-mm plates and incubated at 37°C in a humidified atmosphere containing 5% CO 2 in air. After a 14-day incubation, colonies consisting of Ն40 cells were counted under an inverted microscope.
Western blot analysis
Untreated TC were lysed in buffer containing 50 mM tris(hydroxymethyl)aminomethane-HCl (pH 7.5), 250 mM NaCl, 0.1% Nonidet P-40, 50 mM NaF, 5 mM ethylenediaminetetraacetic acid, 10 g/mL aprotinin, 10 g/mL leupeptin, and 1 mM phenylmethylsulfonyl fluoride. After a freeze/thaw and centrifugation, the supernatants were harvested. A total of 10 g of each protein lysate was electrophoresed on 12% tris(hydroxymethyl)aminomethane-glycine gels (Novex, San Diego, Calif). The proteins were transferred onto 0.2-m nitrocellulose membranes and blocked with a 0.5% casein solution for 1 hour. The membrane was incubated in anti-p53 (Ab-7) (Oncogene Research Products, Cambridge, Mass) or anti-␤-actin (Sigma, St. Louis, Mo), washed, and incubated in either anti-sheep immunoglobulin horseradish peroxidase (Boehringer Mannheim, Indianapolis, Ind) or anti-mouse immunoglobulin horseradish peroxidase (Amersham, Arlington Heights, Ill). The proteins were detected by enhanced chemiluminescence (Amersham).
Statistics
In all experiments, the cells were plated in triplicate, and each experiment was repeated three to five times (n ϭ 9 -15). The mean percentage of inhibition of clonogenic growth is reported and calculated using the following formula: ([mock-infected culture Ϫ experimental culture]/mock-infected cultures) ϫ 100. Means and SEMs were obtained from pooled data. Statistical analysis was performed by two-tailed Student's t tests using SPSS for Windows (SPSS Inc., Chicago, Ill). A P value of Յ.05 was considered to indicate statistical significance.
RESULTS
p53 status of human breast cancer cell lines Expression of endogenous p53 was graded on a semiquantitative scale (Ϫ, Ϯ, ϩ, ϩϩ, ϩϩϩ) after Western blot analysis. Protein supernatants from lysed TC underwent electrophoresis, and p53 expression was detected by Western blotting (Fig 1) and compared with ␤-actin levels as a control for protein loading. The semiquantitative results and the specific point mutation 24 for each cell line studied are shown in Table 1 .
Dose-dependent Adv-p53 reduction in tumor clonogenic growth Five different breast cancer cell lines (1 ϫ 10 5 cells) were infected with Adv-p53 or Adv-␤-gal in a volume of 50 L (Fig 2a) or 2 mL (Fig 2b) for 2 hours at PN to TC ratios ranging from 425:1 to 68,000:1. As shown in Figure 2 , the clonogenic growth of MDA-MB-231, MDA-MB-468, and SKBR-3 cells was inhibited by infection with Adv-p53 in a dose-dependent manner (total loss of clonogenic growth was observed at a PN to TC ratio of Ն2125:1). Complete loss of clonogenic growth was observed at a PN to TC ratio of 42,500:1 for MDA-MB-435, whereas MCF-7 had a 94.7% loss of clonogenic growth with a PN to TC ratio of 68,000:1, which was the largest ratio tested. When the cell lines were treated with the same PN to TC ratio of Adv-p53 within a larger volume (2 mL), the inhibition of clonogenic growth was significantly reduced compared with studies using a 50-L volume. However, in a 2-mL volume, a total loss of clonogenic growth by MDA-MB-231, MDA-MB-468, and SKBR-3 cells was observed at PN to TC ratios of Ն42,500:1. In contrast, the inhibition of clonogenic growth by Adv-p53 was Ͻ50% for MCF-7, even at a PN to TC ratio of 68,000:1. Adv-␤-gal also inhibited clonogenic growth in a dose-dependent manner, although the effectiveness was significantly less than that found with Adv-p53. An inhibition of TC clonogenic growth similar to Adv-␤-gal was observed with an "empty" Adv construct (results not shown).
Volume-dependent Adv-p53 reduction in tumor clonogenic growth MDA-MB-231 and -435 cells (1 ϫ 10
5 /coculture) were tested for volume-dependent Adv-p53 inhibition of clonogenic growth at a PN to TC ratio of 42,500:1 with a 2-hour coincubation and in volumes ranging from 50 to 2400 L (Fig 3) . The breast cancer cell line MDA-MB-231 had a total loss of clonogenic growth at all volumes tested. In contrast, inhibition of clonogenic growth by Adv-␤-gal was significantly lower than that observed with Adv-p53. A p53-specific, dose-dependent, Adv-p53-induced inhibition of clonogenic MDA-MB-435 growth also was observed. Significantly, less inhibition of clonogenic growth by Adv-p53 for MDA-MB-435 cells was observed than with MDA-MB-231 cells, consistent with the limited Adv-mediated transgene expression in this cell line. 33 Time-dependent Adv-p53 reduction in tumor clonogenic growth The clonogenic growth of MDA-MB-231 and -435 cells (1 ϫ 10 5 /coculture) was compared at two different PN to TC ratios (42,500:1 and 4,250:1) in an incubation volume of 100 L or 2 mL. TC were treated with Adv-p53 or Adv-␤-gal for various time periods, ranging from 0.25 to 24 hours (Fig 4) . MDA-MB-231 had a complete loss of clonogenic growth by Adv-p53 at all incubation times, with a high concentration of Adv-p53 (a PN to TC ratio of 42,500:1) in a volume of 100 L. In contrast, incubation in a larger volume of 2 mL and with a PN to TC ratio of 4250:1 revealed an incubation time-dependent loss of clonogenic growth. At a low coincubation volume (a PN to TC ratio of 42,500:1 in 100 L), Adv-p53 also induced a total loss of MDA-MB-435 clonogenic growth 
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when incubated for Ͼ0.5 hours. However, when the Adv-p53 coincubation volume was increased (2-mL coculture), the maximum loss of clonogenic growth of MDA-MB-435 was Յ80%. Adv-␤-gal also inhibited clonogenic growth in a time of coincubation-dependent manner when added in a volume of 100 L.
Effect of PSC on Adv-p53-mediated loss of tumor clonogenic growth MDA-MB-231 (8 ϫ 10 3 or 8 ϫ 10 4 ) cells were cocultured with Adv-p53 in the presence or absence of PMNC (8 ϫ 10 6 ) at a PN of 1 ϫ 10 6 to 3.4 ϫ 10 10 in a volume of 100 L for 4 hours (n ϭ 10). In this study, to clarify the effect of the presence of PSC products and the frequency of TC contamination of the PSC, we plotted clonogenic growth inhibition versus the PN to PMNC ratio (Fig 5a) . These studies used a PN to PMNC ratio of 4250:1 as the highest Adv concentration. As shown in Figure 5a , a total loss of clonogenic TC growth was observed at a PN to PMNC ratio of Ն30:1 in a coculture without PMNC (TC alone). However, coincubation with PMNC significantly reduced the loss of clonogenic tumor growth to 95% with 8 ϫ 10 3 TC (0.1% TC in PMNC) and to 80% with 8 ϫ 10 4 TC (1.0% TC in PMNC) at a PN to PMNC ratio of 30:1. In these instances, a total loss of clonogenic tumor growth required a 5-to 20-fold higher PN of Adv-p53 (PN to PMNC ratio of 1.5 ϫ 10 2 to 4.5 ϫ 10 2 :1). The GM-CFU formation by PMNC incubated with 0.1% TC and Adv-p53 at the various concentrations was quantified to measure hematopoietic function. As shown in Figure 5b , Figure 2 . Clonogenic assay of breast cancer cell lines. Cells were infected with Adv-p53 (F) or Adv-␤-gal (E) at increasing PN to TC ratios (425:1 to 68,000:1) in a volume of 50 L or 2 mL for 2 hours in tubes and assayed for clonogenic growth as described in Materials and Methods. The study was repeated four times, with six replicates per sample in each study. Inhibition of colony formation is plotted as a percentage of untreated cells. Bars, Ϯ SD; #, significant inhibition of clonogenic growth by Adv-p53 versus by Adv-␤-gal; &, significant inhibition of clonogenic growth by Adv-p53 or Adv-␤-gal in 50 L versus 2 mL; @, significant inhibition of clonogenic growth by Adv-p53 or Adv-␤-gal versus a PN to TC ratio of 68,000:1 or 42,500:1. P values are Ͻ.05.
at any Adv-p53 concentration, PMNC did not lose significant function as measured by GM-CFU formation after incubation for 4 hours.
Log killing activity of Adv-p53
As shown in Figure 6 , the coincubation of 10 6 TC, with or without 10 8 PMNC, for 4 hours and the subsequent culturing of these cells as equal aliquots in 60-mm plates (plated in triplicate) resulted in confluent monolayers due to a high number of TC (3.33 ϫ 10 5 ) added per plate. However, no colonies were observed in plates from 1 ϫ 10 6 TC coincubated with Adv-p53 at PN to PMNC ratios of 4250 or 425 for 4 hours. In contrast, cell growth was observed in plates from 1 ϫ 10 6 TC treated with Adv-p53 at a PN to PMNC ratio of 42.5 for 4 hours with or without PMNC. In addition, at all concentrations of Adv-p53 addition to the cocultures of TC with PMNC, no significant loss of GM-CFU function was observed (data not shown).
DISCUSSION
As demonstrated in many studies, TC can contaminate PSC products. 15, 16 In the cases of lymphoma, leukemia, breast cancer, and neuroblastoma patients, these contaminating TC have the capacity for clonogenic growth in vitro. 15,34 -36 Gene-marking studies have demonstrated that reinfused TC can contribute to disease relapse, [7] [8] [9] and consequently to a poor clinical outcome. 34, 36, 37 In breast cancer, the contribution of reinfused TC to clinical outcome remains unclear. 12,38 -40 Recent prospective studies suggest a poor prognosis for breast cancer patients with immunocytochemically detectable TC in the BM. 41 Furthermore, breast cancer cells can be mobilized into PSC products that have clonogenic growth potential in vitro. 15 These observations suggest that the removal (purging) of TC from stem cell products may have a significant effect on clinical outcome. Indeed, the clinical purging of all breast cancer cells from BM with 4-hydroperoxycyclophosphamide has been reported by Osborne et al 42 to improve clinical outcome.
Various approaches for the ex vivo purging of TC from stem cell products have been developed. The use of monoclonal antibodies against membrane antigens with cytotoxic drugs or toxins, phototherapy, or biological response modifiers can reduce tumor contamination by 1-3 logs. 43 The selection of CD34 ϩ hematopoietic progenitor cells also has been used to reduce TC reinfusion, although this strategy may be slightly less effective (1-2.5 logs). However, purging using cytotoxic drugs often leads to delayed engraftment, 44 and purging by CD34 ϩ cell selection may inhibit immune recovery. 45 Furthermore, the loss of p53 function is known to be associated with TC resistance to antitumor therapy. 46, 47 Thus, the p53 mutations that are observed in TC may limit the effect of "traditional" purging techniques, whereas the induction of high levels of wt p53 production can suppress the growth of cancer cells with altered p53 expression. 24, 28, 48 We report that infection with Adv-p53 vectors can successfully decrease the clonogenic growth of human TC without an effect on the function of hematopoietic progenitor cells. 26, 27 In the present studies, a 2-log reduction in clonogenic growth was observed with a 1% TC contamination. However, similar to the studies of Garcia et al, 49 a log killing assay was performed in a limited volume of media containing TC at 1 ϫ 10 6 and/or PMNC at 1 ϫ 10 8 /mL. No TC growth was observed after incubation with Adv-p53 at a PN of 4.3 ϫ 10 11 /mL (a PN to PMNC ratio of 4.3 ϫ 10 3 :1) in the presence or absence of PMNC. Thus, we were able to demonstrate a 6-log TC killing activity of Adv-p53 in PSC products without loss of hematopoietic function. This successful, high log killing activity of Adv-p53 without an effect on hematopoietic function is highly competitive with all other purging techniques and represents an increase of activity of 2-4 logs. As reported previously, breast cancer cell lines have a high number of Adv receptors that facilitate Adv-mediated gene transfer, 50, 51 presumably by receptor-mediated endocytosis. 52, 53 Furthermore, Adv infection has been shown to result in transgene expression in breast cancer cells at a higher level than in hematopoietic stem cell products. 24, 54, 55 This apparent selectivity may be beneficial to the purging of TC from stem cell products. Several transgenes have been used for purging, including thymidine kinase, cytosine deaminase, and p53. 23, 47, 49, 52, 53 In contrast to p53, the use of thymidine kinase or cytosine deaminase requires the coculture or injection of the patient with ganciclovir or 5-fluorocytosine for 7-10 days, limiting its potential efficiency. As shown here, no effect on GM-CFU function was observed with Adv-p53 coculture, confirming our previous studies that included analysis not only of GM-CFU but also of high proliferation potential-colony forming cells and burst forming uniterythrocytes. 26 The cell lines examined in this study had different p53 mutations, including the amino acid substitutions of Arg to His (amino acids 273, 175, and 280) and Gly to Glu (amino acid 266) ( Table 1 ). All of the cell lines examined with mutated p53 were sensitive to p53 inhibition of clonogenic growth when treated with Adv-p53 in a small volume. These results suggest that both the specific mutated amino acid and the levels of p53 expression did not affect Adv-p53 inhibition of clonogenic growth at a high Adv PN or in a small volume. Indeed, even large incubation volumes and low Adv concentrations could result in a total inhibition of clonogenic growth when MDA-MB-231 cells were infected with Adv-p53 in cocultures for 24 hours. Moreover, cells relatively refractory 33 to Adv transduction and Adv-p53 inhibition (MDA-MB-435) could undergo a complete loss of clonogenic growth at a PN to TC ratio of 4250:1 in a volume of 100 L with an 8-hour coincubation.
In studies from other laboratories, MDA-MB-231 cells were reported to have a 50% growth inhibition after coculture with Adv-p53 at a multiplicity of infection (MOI) of 1:1 in volume of 100 L with a 2-hour coincubation 50 or at a MOI of 12:1 in a volume of 200 L with a 18-to 24-hour coincubation. 24 In our studies, a 70% loss of clonogenic growth was observed at a comparable Adv-p53 concentration (MOI of 10:1, PN to TC ratio of 425:1) in a volume of 50 L after a 2-hour incubation with Adv-p53. Taken together, these results suggest that the coincubation volume is important and emphasize the limitations of MOI as a measure of Adv dose. 31 In studies of MDA-MB-468 or SKBR-3 cells, we found a greater inhibition of clonogenic growth (Ͼ70% at a MOI of 10:1 in a volume of 50 L after a 2-hour incubation) compared with data reported previously, perhaps due to the use of a clonogenic versus a [ 3 H]thymidine incorporation assay. Harris et al 24 also report that SKBR-3 appears to be less sensitive to p53 reintroduction than other p53 mutated cell lines following comparable transduction. However, in their studies, treatment in small volumes resulted in uniformly high levels of transgene expression, which is consistent with our results.
In our studies on the infection of MCF-7 cells with Adv in a volume of 2 mL, there was no reduction in clonogenic growth at any Adv concentration tested. In contrast, clonogenic growth was significantly decreased (a PN to TC ratio of Ն4250:1) in a coincubation volume of 50 L. However, this inhibition was not p53-specific, because Adv-␤-gal and Adv-p53 had similar levels of activity. As reported previously, cell lines containing wt p53 are not growth-inhibited by Adv-p53 to the same extent as p53-deficient TC lines. 24, 48 It has been reported that the frequency of Adv infection is similar between the MCF-7 cell line and other breast cancer cell lines carrying mutated p53. 50, 54 In our studies, Adv-p53 showed a Ն90% growth inhibition of MCF-7 at a high PN to TC ratio (68,000:1). A similar loss of clonogenic growth (90%) by MCF-7 cells was observed by Wroblewski et al 23 at a MOI of 200:1 after 2 hours of incubation. In addition, they reported a complete loss of clonogenic growth when MCF-7 cells were mixed with a PSC product and infected with Adv-p53 at a MOI of 200:1. Taken together, these results suggest that Advp53 can inhibit the growth of TC that contain wt p53 or have a decrease in Adv transduction. 48 Expression of wt p53 protein in p53-deficient TC can suppress cell growth. 20,25,56 -58 In addition, the cytopathic effects of replication-deficient recombinant human Adv, regardless of the encoded transgene, can inhibit TC clonogenic growth. The nonspecific cytotoxicity of Adv for TC occurs by mechanisms that are not yet fully understood. However, nonspecific cytotoxicity has been reported previously for hepatocellular colon carcinoma cells, 59 prostate cells, 60 squamous cell carcinoma of the head and neck, 61 and bladder carcinoma. 62 This nonspecific effect varies with the cell line examined and, to a lesser extent, with the assay used. Recently, Demers et al 62 suggested that retinoblastoma gene expression may influence the nonspecific toxicity of Adv p53, suggesting one potential mechanism. Our results demonstrate that Adv-mediated inhibition of TC clonogenic growth is most apparent at a high PN to TC ratio, a small coincubation volume, and/or a longer incubation time. We conclude that TC-contaminated PSC products can be purged using a short duration Adv-p53 incubation, which may limit gene transfer to stem cells, 26, 27 as was recently discussed. 55 The relative resistance of stem cell products 26, 27, 54, 55 to replication-deficient recombinant human Adv suggests that nonspecific Adv cytotoxicity is limited to TC and that Adv-p53 can effectively purge TC from PSC products (Fig 5a) . Thus, the use of Adv purging, perhaps in combination with the isolation of CD34 ϩ cells, may be of benefit. Furthermore, Adv-p53 purging appears to be less toxic to progenitor cells than most other purging strategies using positive selection or cytotoxic agents. We have demonstrated previously that the coincubation of stem cell products with Adv-␤-gal or Adv-p53 has no effect on GM-CFU, burst-forming uniterythrocyte, and high proliferation potential-colony forming cell assays, suggesting a lack of effect on both committed and multipotent progenitor cells. 26 Nonetheless, only a clinical trial will be able to determine the effect of this purging strategy on engraftment as well as other unforeseen toxicity issues. 27 
